Bluebird Bio, INC Form 4 insider transactions
Director Elisabeth Leiderman reports acquisition of 24,900 shares and disposal of shares of Bluebird Bio common stock, along with stock option grants.
Director Mark Vachon acquired shares and options in Bluebird Bio on November 6, 2024, according to a Form 4 filing.
Richard Colvin, Chief Medical Officer of bluebird bio, Inc., was granted 50,000 restricted stock units on September 30, 2024, vesting over four years.
Form 4: Bluebird Bio Executive Joseph Vittiglio Reports Acquisition of 50,000 Shares of Common Stock
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., reports the acquisition of 50,000 shares of common stock through restricted stock units.
Bluebird Bio's Chief Financial Officer, O. James Sterling, was granted 100,000 restricted stock units on September 30, 2024, vesting over a four-year period.
Director Michael Cloonan acquired 37,350 shares of Bluebird Bio common stock on September 30, 2024, through restricted stock units vesting over three years.
Thomas Klima, Chief Commercial & Operating Officer of bluebird bio, received a grant of 50,000 restricted stock units and sold 1,006 shares to cover tax obligations.
Andrew Obenshain, CEO of Bluebird Bio, reports acquisition of 130,000 shares of common stock and disposition of 34,780 shares to cover tax obligations related to vesting restricted stock units.
Bluebird Bio's Chief Financial Officer, O. James Sterling, acquired 300,000 stock options on July 1, 2024, according to a Form 4 filing.
Michael Cloonan, a director at bluebird bio, acquired stock options for 74,775 shares at an exercise price of $0.85 on June 20, 2024.
Thomas J. Klima, Chief Commercial & Operating Officer of bluebird bio, Inc., sold 3,834 shares of common stock on June 3, 2024, to cover tax withholding obligations.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., reported the sale of 6,770 shares to cover tax obligations and the grant of a stock option for 199,000 shares.
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., was granted stock options to purchase 199,000 shares of common stock.
Bluebird Bio's CEO, Andrew Obenshain, sold 6,095 shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units, while also being granted a stock option to purchase 650,000 shares.
Christopher Krawtschuk, CFO of bluebird bio, Inc., was granted stock options on March 1, 2024, according to a Form 4 filing with the SEC.
Thomas Klima, Chief Commercial & Operating Officer of bluebird bio, reported the sale of 4,573 shares to cover tax obligations and the grant of a stock option for 199,000 shares.